New Key Statistics Module, Z-Score and F-Score
OHEL:REMEDY Key Ratios
| Market Cap € M | 190.04 |
| Enterprise Value € M | 171.01 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 64.88 |
| Price/Book | 2.76 |
| Price/Sales | 17.83 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) € M | 10.00 |
| EPS (TTM) € | -0.16 |
| Beneish M-Score | -2.46 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -125.10 |
| EV-to-EBIT | -59.34 |
| EV-to-EBITDA | -83.14 |
| PEG | -- |
| Shares Outstanding M | 13.57 |
| Net Margin (%) | -21.44 |
| Operating Margin % | -30.97 |
| Pre-tax Margin (%) | -28.43 |
| Quick Ratio | 1.45 |
| Current Ratio | 1.45 |
| ROA % (ttm) | -2.54 |
| ROE % (ttm) | -3.12 |
| ROIC % (ttm) | -4.59 |
| Dividend Yield % | -- |
| Altman Z-Score | 4.77 |
OHEL:REMEDY Number of Guru Trades
OHEL:REMEDY Volume of Guru Trades
Gurus Latest Trades with OHEL:REMEDY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OHEL:REMEDY is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers